Literature DB >> 14665655

C-reactive protein and the risk of developing hypertension.

Howard D Sesso1, Julie E Buring, Nader Rifai, Gavin J Blake, J Michael Gaziano, Paul M Ridker.   

Abstract

CONTEXT: Although it has been hypothesized that hypertension is in part an inflammatory disorder, clinical data linking inflammation with incident hypertension are scarce.
OBJECTIVE: To examine whether C-reactive protein levels, a marker of systemic inflammation, are associated with incident hypertension. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study that began in 1992 of 20 525 female US health professionals aged 45 years or older who provided baseline blood samples with initially normal levels of blood pressure (BP) (systolic BP <140 mm Hg and diastolic BP <90 mm Hg, and no history of hypertension or antihypertensive medications) and then followed up for a median of 7.8 years for the development of incident hypertension. Plasma C-reactive protein levels were measured and baseline coronary risk factors were collected. MAIN OUTCOME MEASURE: Incident hypertension, defined as either a new physician diagnosis, the initiation of antihypertensive treatment, or self-reported systolic BP of at least 140 mm Hg or a diastolic BP of at least 90 mm Hg.
RESULTS: During follow-up, 5365 women developed incident hypertension. In crude models, the relative risks (RRs) and 95% confidence intervals (CIs) of developing hypertension from the lowest (referent) to the highest levels of baseline C-reactive protein were 1.00, 1.25 (95% CI, 1.14-1.40), 1.51 (95% CI, 1.35-1.68), 1.90 (95% CI, 1.72-2.11), and 2.50 (95% CI, 2.27-2.75) (linear trend P<.001). In fully adjusted models for coronary risk factors, the RRs and 95% CIs were 1.00, 1.07 (95% CI, 0.95-1.20), 1.17 (95% CI, 1.04-1.31), 1.30 (95% CI, 1.17-1.45), and 1.52 (95% CI, 1.36-1.69) (linear trend P<.001). C-reactive protein was significantly associated with an increased risk of developing hypertension in all prespecified subgroups evaluated, including those with very low levels of baseline BP, as well as those with no traditional coronary risk factors. Similar results were found when treating C-reactive protein as a continuous variable and controlling for baseline BP.
CONCLUSION: C-reactive protein levels are associated with future development of hypertension, which suggests that hypertension is in part an inflammatory disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14665655     DOI: 10.1001/jama.290.22.2945

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  261 in total

1.  Polymorphisms in LEP and NPY genes modify the response to soluble fibre Plantago ovata husk intake on cardiovascular risk biomarkers.

Authors:  Anna Crescenti; Rosa Solà; Rosa M Valls; Anna Anguera; Lluís Arola
Journal:  Genes Nutr       Date:  2012-06-06       Impact factor: 5.523

2.  Periodontal bacteria and hypertension: the oral infections and vascular disease epidemiology study (INVEST).

Authors:  Moïse Desvarieux; Ryan T Demmer; David R Jacobs; Tatjana Rundek; Bernadette Boden-Albala; Ralph L Sacco; Panos N Papapanou
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

3.  Serum vitamin D level and prehypertension among subjects free of hypertension.

Authors:  Charumathi Sabanayagam; Anoop Shankar; Shanmugasundaram Somasundaram
Journal:  Kidney Blood Press Res       Date:  2011-09-21       Impact factor: 2.687

Review 4.  Antihypertensive effects of aspirin: what is the evidence?

Authors:  Leonelo E Bautista; Lina M Vera
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

5.  Use of statins and blood pressure.

Authors:  Dana E King; Arch G Mainous; Brent M Egan; Marty Player; Mark E Geesey
Journal:  Am J Hypertens       Date:  2007-09       Impact factor: 2.689

6.  Uric acid and insulin sensitivity and risk of incident hypertension.

Authors:  John P Forman; Hyon Choi; Gary C Curhan
Journal:  Arch Intern Med       Date:  2009-01-26

Review 7.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 8.  Hypertension and the metabolic syndrome.

Authors:  John A Farmer
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 9.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

10.  Neighborhood walkable urban form and C-reactive protein.

Authors:  Katherine King
Journal:  Prev Med       Date:  2013-10-03       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.